Thrilled to have contributed to this work led by @jgcastillo.bsky.social during his PhD at UC Berkeley w/ Michel DuPage. Targeting FSP1 in T cells boosts anti-tumor immunity by relieving Treg suppression, revealing a new immunomodulatory therapeutic axis. www.science.org/doi/10.1126/...
www.science.org
Deletion of Aifm2 disrupts Treg cell immunosuppression within tumors without inciting autoimmune pathology in mice.